| 老年HER2阴性晚期乳腺癌患者应用氟维司群联合瑞博西林治疗的临床观察 |
| |
| 引用本文： | 史奇峰,朱雄林,靖一专,曹丹丹. 老年HER2阴性晚期乳腺癌患者应用氟维司群联合瑞博西林治疗的临床观察[J]. 老年医学与保健, 2021, 27(2): 241-244 |
| |
| 作者姓名： | 史奇峰 朱雄林 靖一专 曹丹丹 |
| |
| 作者单位： | 武汉市中心医院新洲院区(武汉市新洲区人民医院)胸外肿瘤外科,湖北武汉430400;武汉市中心医院新洲院区(武汉市新洲区人民医院)感染科,湖北武汉430400;武汉市中心医院新洲院区(武汉市新洲区人民医院)妇科,湖北武汉430400;上海交通大学医学院附属仁济医院妇科,上海200127 |
| |
| 摘 要： | 目的 观察老年HER2阴性晚期乳腺癌患者应用氟维司群联合瑞博西林的治疗效果.方法 选取在武汉市中心医院新洲院区2017年6月-2019年6月期间进行内分泌治疗的乳腺癌晚期患者150例,依据随机数字表法分为观察组和对照组,每组75例.对照组予以氟维司群治疗,观察组予以氟维司群联合瑞博西林治疗.疗程结束后,评估并比较2组治...
|
| 关 键 词： | 老年 HER2阴性 晚期乳腺癌 氟维司群 瑞博西林 临床疗效 |
Clinical observation of fulvestrant combined with reboxillin in the treatment of elderly patients with HER2-negative advanced breast cancer |
| |
| Shi Qifeng,Zhu Xionglin,Jing Yizhuan,Cao Dandan. Clinical observation of fulvestrant combined with reboxillin in the treatment of elderly patients with HER2-negative advanced breast cancer[J]. Geriatrics & Health Care, 2021, 27(2): 241-244 |
| |
| Authors: | Shi Qifeng Zhu Xionglin Jing Yizhuan Cao Dandan |
| |
| Affiliation: | (Department of Extrathoracic Tumor Surgery,Xinzhou Branch(People's Hospital of Xinzhou District)of Central Hospital ofWuhan City,Wuhan,Hubei,430400,P.R.China;Department of Infectious Disease,Xinzhou Branch(People's Hospital of Xinzhou District)of Central Hospital ofWuhan City,Wuhan,Hubei,430400,P.R.China;Department of Gynaecology,Xinzhou Branch(People's Hospital of Xinzhou District)of Central Hospital of Wuhan City,Wuhan,Hubei,430400,P.R.China;Department of Gynaecology,Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University,Shanghai,200127,P.R.China) |
| |
| Abstract: | Objective To observe the therapeutic effect of fulvestrant combined with reboxillin in elderly patients with human epidermal growth factor receptor 2(HER2)-negative advanced breast cancer.Methods 150 patients with HER2-negative advanced breast cancer who received endocrine therapy in Xinzhou Branch of Central Hospital of Wuhan City from June 2017 to June 2019 were selected and divided randomly into observation group and control group,75 cases in each group.The control group was treated with fulvestrant,and the observation group was treated with fulvestrant combined with reboxillin.After the treatment,the therapeutic effect,medication safety and follow-up situation were evaluated and compared between the two groups.Results After treatment,the clinical benefit rate (CBR)and objective response rate(ORR)of the observation group were significantly higher than those of the control group(P<0.05).There was no significant difference in the adverse reactions between the two groups in fatigue,joint pain,hot tide,numbness of limbs,gastrointestinal reaction and liver function damage(P>0.05),and the incidence of adverse reactions of neutropenia and leucopenia in the observation group was significantly higher than that in the control group,but the progression-free survival(PFS)(24.74±3.43 months)and overall survival(OS)(35.87±5.26 months)of the observation group were significantly longer than those of the control group[PFS(17.19±2.62)months and OS(25.28±4.29)months](P<0.05).Conclusion The treatment of elderly patients with HER2-negative advanced breast cancer with fulvestrant combined with reboxillin can effectively improve the clinical benefit rate and objective remission rate,significantly prolong PFS and OS,and its safety is good. |
| |
| Keywords: | elderly HER2-negative advanced breast cancer fulvestrant reboxillin clinical efficacy |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
